Hemato-oncologic
Conditions
Interventions
The study group will receive 3-BC-PCs, the control group 5-BC-PCs.
Sponsors
HagaZiekenhuis
Eligibility
Inclusion criteria
Inclusion criteria: • Age = 18 years. • Having a hemato-oncologic disease. • Expected = 2 platelet transfusion requirements during current hospitalization. • Signed informed consent.
Exclusion criteria
Exclusion criteria: • Known immunological refractoriness to platelet transfusions. • HLA- and/or HPA-alloimmunization and/or clinical relevant auto-antibodies. • Indications to use HLA-typed platelet concentrates. • Indications to use hyper-concentrated (plasma-reduced) platelet concentrates, for example patients with known severe allergic reactions or transfusion-associated circulatory overload (TACO). • Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of days with grade 1b+2 bleeding according to the Bleeding Severity Measurement Scale (BSMS) as primary endpoint. | — |
Secondary
| Measure | Time frame |
|---|---|
| • total number of platelets received • total number of individual buffy coats received • the 1 and 24 hour CI • the 1 and 24 hour CCI • percentage of patients with at least one bleeding grade 1b+2 according to the BSMS • percentage of patients and percentage of days per patient with at least one = clinically relevant minor bleeding grade according to the ISTH bleeding scale • rate of HLA alloimmunization • adverse transfusion reactions • platelet transfusion interval • total number of platelet transfusions • total number of red cell and plasma transfusions • association between albumin/creatinine in urine and/or CRP and clinically relevant bleeding grades according to the BSMS • cost benefit analysis | — |
Contacts
Public ContactPieter van der Meer
HagaZiekenhuis
Outcome results
None listed